ClinicalTrials.gg
RecruitingNCT07840144Updated Nov 19, 2026

Lower Body Negative Pressure to Validate Physiological Monitors

An interventional study of Lower Body Negative Pressure with Noninvasive Physiological Monitoring in Physiological Stress, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this research is to test the accuracy of non-invasive physiological monitors while the body responds to different levels of lower body negative pressure (LBNP).

02

Conditions studied

  • Physiological Stress

Keywords

  • Hemodynamic Monitoring
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-obese (\<30)
  • Non-smokers
  • Free of any systemic diseases including hypertension, diabetes, coronary artery disease, neurologic disease, or any other major medical co-morbidity.
  • Women will be either surgically sterilized or non-pregnant as determined by a urine pregnancy test (within 48 hours of the study day)

Exclusion criteria

Exclusion Criteria:

  • Individuals taking GLP-1 medications or compounds known to affect responses of the autonomic nervous system to orthostatic stress (e.g., β-blockers)
  • Pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Healthy Volunteers Undergoing Lower Body Negative Pressure

    Healthy adult participants will complete one study visit involving graded lower body negative pressure while standard physiological reference measurements and noninvasive investigational physiological monitor data are collected.

    Diagnostic Test: Lower Body Negative Pressure with Noninvasive Physiological Monitoring

Interventions

  • Diagnostic testLower Body Negative Pressure with Noninvasive Physiological Monitoring

    Participants will undergo a graded lower body negative pressure protocol using suction levels of 15, 30, 45, 60, 70, 80, 90, and 100 mmHg, each for up to 5 minutes or until presyncopal symptoms or other termination criteria occur. During the procedure, validated reference physiological measurements and investigational noninvasive monitor signals will be collected simultaneously.

06

What researchers measure

Primary outcomes

  1. Arterial Oxygen Saturation During Lower Body Negative Pressure

    Arterial oxygen saturation will be measured during lower body negative pressure using noninvasive physiological monitors

    Time frame: During the single study visit, from baseline through completion of the lower body negative pressure protocol, up to 40 minutes

  2. ECG Waveform During Lower Body Negative Pressure

    ECG waveform will be measured during lower body negative pressure using noninvasive physiological monitor

    Time frame: During the single study visit, from baseline through completion of the lower body negative pressure protocol, up to 40 minutes

  3. Respiratory Rate During Lower Body Negative Pressure

    Respiratory rate will be measured during lower body negative pressure using noninvasive physiological monitors

    Time frame: During the single study visit, from baseline through completion of the lower body negative pressure protocol, up to 40 minutes

  4. Plethysmography Signals During Lower Body Negative Pressure via physiological monitors

    Plethysmography signals will be measured during lower body negative pressure from the pulse oximetry. Reported as a non-invasive research metric of central blood volume.

    Time frame: During the single study visit, from baseline through completion of the lower body negative pressure protocol, up to 40 minutes

  5. Heart rate During Lower Body Negative Pressure

    Heart rate will be measured during lower body negative pressure using noninvasive physiological monitors

    Time frame: During the single study visit, from baseline through completion of the lower body negative pressure protocol, up to 40 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 24, 2026
StartActual
Nov 5, 2026was Sep 2026
Primary completionEst.
Sep 28, 2028
CompletionEst.
Sep 28, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Nov 5, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Sep 30, 2026→Nov 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07840144
Lead sponsor
Mayo Clinic
Responsible party
Michael J. Joyner, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 24, 2026
Start date
Nov 5, 2026
Primary completion
Sep 28, 2028 (estimated)
Completion
Sep 28, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Pamela Engrav
Contact
engrav.pamela@mayo.edu
507-255-6938
Ronee Harvey
Contact
harvey.ronee@mayo.edu
507-255-1466
Michael J. Joyner, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion